Lastacaft
| Lastacaft | |
|---|---|
| DOSAGE | 1 gtt qD |
| GENERIC | alcaftadine 0.25% |
| SIZE | 3mL |
| INDICATIONS | LASTACAFT® is an H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. |
| MECHANISM OF ACTION | Combo Mast Cell Stabilizer / Anti H1 |
| MICROBIOLOGY | Alcaftadine is an H1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated. |
| CONTRAINDICATIONS & WARNINGS | LASTACAFT® is contraindicated in patients with hypersensitivity to any component in the product. |
| PEDIATRIC USE | Safety and effectiveness in pediatric patients below the age of 2 years have not been established. |
| PREGNANCY | Category B. There are no adequate and well-controlled studies with LASTACAFT® in pregnant women to inform a drug associated risk. There are limited data with the use of alcaftadine eye drops in pregnant women. In embryofetal studies in rats and rabbits, oral administration of alcaftadine during the period of organogenesis did not produce maternal or embryofetal toxicity at clinically relevant doses. |
| NOTE | preserved with BAK .005% |